Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor

[1]  A. Jakubowska,et al.  Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer , 2021, Cancers.

[2]  A. Jakubowska,et al.  Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland , 2020, Cancers.

[3]  L. Forétova,et al.  Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer , 2020, Cancers.

[4]  A. Jakubowska,et al.  The spectrum of mutations predisposing to familial breast cancer in Poland , 2019, International journal of cancer.

[5]  R. Vierkant,et al.  Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer , 2019, Journal of Medical Genetics.

[6]  Publisher's Note , 2018, Anaesthesia.

[7]  Jaime Prat,et al.  Pathology of borderline and invasive cancers. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[8]  Steffen Hauptmann,et al.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria , 2016, Virchows Archiv.

[9]  C. Borgfeldt,et al.  Long‐term survival in women with borderline ovarian tumors: a population‐based survey of borderline ovarian tumors in Sweden 1960–2007 , 2016, Acta obstetricia et gynecologica Scandinavica.

[10]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[11]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Chiang,et al.  Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model. , 2015, Taiwanese journal of obstetrics & gynecology.

[13]  A. Jakubowska,et al.  Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. , 2015, The Lancet. Oncology.

[14]  A. Jakubowska,et al.  Recurrent mutations of BRCA1 and BRCA2 in Poland: an update , 2015, Clinical genetics.

[15]  E. Darai,et al.  Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors. , 2014, American journal of obstetrics and gynecology.

[16]  J. Park,et al.  Hereditary Risk Evaluation for Borderline Ovarian Tumors Based on Immunohistochemistry , 2014, Journal of menopausal medicine.

[17]  P. Palczewski,et al.  Differentiation of Ovarian Cancers From Borderline Ovarian Tumors on the Basis of Evaluation of Tumor Vascularity in Multi–Row Detector Computed Tomography—Comparison With Histopathology , 2013, International Journal of Gynecologic Cancer.

[18]  M. Zikan,et al.  Diagnosis, treatment, and follow-up of borderline ovarian tumors. , 2012, The oncologist.

[19]  A. Çeti̇n,et al.  Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors , 2012, Diagnostic Pathology.

[20]  B. Davidson,et al.  Borderline ovarian tumours. , 2012, Best practice & research. Clinical obstetrics & gynaecology.

[21]  A. Stembalska,et al.  Irrelevance of CHEK2 variants to diagnosis of breast/ovarian cancer predisposition in Polish cohort , 2011, Journal of Applied Genetics.

[22]  C. Desimone,et al.  Ten-Year Relative Survival for Epithelial Ovarian Cancer , 2011, Obstetrics and gynecology.

[23]  L. Holmberg,et al.  Borderline ovarian tumors in Sweden 1960–2005: Trends in incidence and age at diagnosis compared to ovarian cancer , 2008, International journal of cancer.

[24]  P. V. van Diest,et al.  A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: case report and review of literature , 2006, International Journal of Gynecologic Cancer.

[25]  J. Lubiński,et al.  CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. , 2006, Gynecologic oncology.

[26]  N. Agnantis,et al.  Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. , 2006, Histology and histopathology.

[27]  I. Shih,et al.  Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges , 2005, Clinical Cancer Research.

[28]  B. Modan,et al.  Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. , 2005, Gynecologic oncology.

[29]  D. Bell,et al.  Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.

[30]  J. Lubiński,et al.  CHEK2 is a multiorgan cancer susceptibility gene. , 2004, American journal of human genetics.

[31]  E. Hovig,et al.  BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study , 2004, British Journal of Cancer.

[32]  J. Lubiński,et al.  A novel founder CHEK2 mutation is associated with increased prostate cancer risk. , 2004, Cancer research.

[33]  P. Hartge,et al.  Survival among women with borderline ovarian tumors and ovarian carcinoma , 2004, Cancer.

[34]  A. Jakubowska,et al.  Hereditary ovarian cancer in Poland , 2003 .

[35]  E. Trimble,et al.  Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. , 2002, Gynecologic oncology.

[36]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[37]  B. Modan,et al.  Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. , 1998, Journal of the National Cancer Institute.

[38]  D. Easton,et al.  Contribution of BRCA1 mutations to ovarian cancer. , 1997, The New England journal of medicine.

[39]  E. Kohn,et al.  Borderline ovarian tumors. , 1996, The American journal of medicine.

[40]  D. Lahiri,et al.  DNA isolation by a rapid method from human blood samples: Effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality , 1993, Biochemical Genetics.

[41]  V. Abeler,et al.  Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". , 2009, European journal of gynaecological oncology.

[42]  P. Morice.  Borderline tumours of the ovary and fertility. , 2006, European journal of cancer.